GlassScriptPhysician profile
David Makover
NPI 1407968787
$6,590.37
in general payments reported to CMS, 2019-2025
28 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $378 · 2021: $713 · 2022: $1,080 · 2023: $1,306 · 2024: $1,091 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.72 | 2020-2025 | |
| Ucb, INC. | $701.83 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $629.01 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Pfizer INC. | $461.04 | 2019-2025 | |
| Janssen Biotech, INC. | $441.17 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Ani Pharmaceuticals, INC. | $421.93 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $374.53 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $322.60 | 2020-2025 | Acthar |
| Lilly USA, LLC | $278.84 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $229.68 | 2020-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $227.49 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $162.55 | 2023 | Krystexxa |
| Genzyme Corporation | $144.73 | 2019-2025 | |
| Organon LLC | $128.24 | 2022-2025 | Renflexis, Hadlima |
| Depuy Synthes Sales INC. | $123.35 | 2023-2024 | Orthovisc |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $114.10 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.92 | 2022-2025 | Cyltezo, Ofev |
| Alvogen INC | $94.24 | 2023-2025 | Teriparatide |
| Fresenius Kabi USA, LLC | $81.10 | 2023-2024 | Idacio |
| Novartis Pharmaceuticals Corporation | $80.75 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $42.76 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $41.48 | 2024 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2023 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $28.75 | 2024 | Strensiq |
| Mylan Institutional INC. | $20.66 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $20.56 | 2020 | |
| Medexus Pharma, INC. | $17.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Makover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.